Three years ago, peptide access meant convincing a primary-care doctor to write a prescription — or buying gray-market vials online. Today the dominant path is telehealth, and the category has fragmented into three recognizable lanes. Each has different economics, different clinical depth, and different risks. Here's the landscape, sourced and current.
Lane 01 — GLP-1 specialty telehealth (Hims, Ro, Henry Meds, Eden, Mochi, Found, WeightWatchers Clinic): Highest patient volume. Quick onboarding. Wide spread on price and clinical depth. Insurance-covered or cash-pay. Best for weight loss / diabetes if you fit a standard profile.
Lane 02 — Manufacturer direct-to-consumer (Lilly Direct for Zepbound, NovoCare for Wegovy): Newer category, accelerating fast. Lowest legitimate cash-pay pricing currently available. Less hand-holding through dosing and side effects. Best if you know what you want and want manufacturer-direct economics.
Lane 03 — Hormone optimization & longevity clinics (Defy Medical, Maximus, Lifeforce, Optispan, Function Health): Higher clinical depth, broader peptide menus including growth hormone peptides and NAD+. Higher cost. Real ongoing prescriber relationships. Best if you want a doctor who actually thinks about peptides for a living.
Three structural factors reshaped peptide access between 2022 and 2026, and the result is a market where most patients now bypass primary-care entirely.
When the GLP-1 obesity wave broke in 2022, primary-care offices were overwhelmed. The standard appointment for evaluating a weight-loss medication is 30–45 minutes; insurance authorization adds 4–6 weeks of paperwork; and most PCPs hadn't been trained to titrate GLP-1s for weight management indications. Telehealth platforms designed around this exact use case could intake, evaluate, and prescribe in days rather than months.
From 2022 through late 2024, FDA shortages of brand-name semaglutide and tirzepatide allowed compounding pharmacies to produce versions of these drugs under Section 506C. A wave of cash-pay telehealth platforms built businesses around compounded GLP-1, often pricing at $179–$249/month versus brand-name list prices of $1,000–$1,300/month. The shortage exception ended in 2025 — tirzepatide officially resolved October 2024, semaglutide February 2025 — and the FDA has since proposed permanently closing the compounding pathway. (See our full analysis on what compounded GLP-1 means in 2026.) The platforms that survived shifted to brand-name distribution; some are still selling compounded product in regulatory gray zones.
The most consequential 2025–2026 development. Eli Lilly launched Lilly Direct selling Zepbound vials directly to qualifying cash-pay patients at sharply reduced prices. Novo Nordisk followed with NovoCare offering Wegovy at $349/month cash-pay. Both bypass the telehealth middleman entirely. The pharma companies decided that their cash-pay revenue was too valuable to leave on the table for the telehealth platforms to take a cut from.
The combined effect of these three forces is a market with three distinct lanes — and a patient population that often doesn't realize how different they are.
Three figures that frame the scale and growth trajectory:
Two practical things to take from these numbers. First, GLP-1s in 2026 are a top-10 prescription drug class by spend — this is no longer niche specialty medicine. Second, the cash-pay floor has dropped meaningfully in the last year. The economic case for "compounded GLP-1 because brand-name is unaffordable" has weakened significantly since manufacturer DTC launched.
The largest segment by patient volume. Examples: Hims/Hers, Ro, Henry Meds, Eden, Mochi Health, Found, WeightWatchers Clinic.
Most platforms in this lane share a similar shape: an online intake form (medical history, weight goals, contraindications), an asynchronous review by a licensed prescriber (often via questionnaire plus optional video), and direct shipment from a partner pharmacy. The best operate with real prescriber consultations and proper chart notes. The weakest are checkbox-and-ship operations where the "consultation" is a 60-second nominal review.
Cash-pay programs typically run $179–$349/month for compounded versions (where still available legally) or somewhat higher for brand-name. Insurance-covered programs handle prior authorization on the patient's behalf, often closing in 3–10 business days — versus 4–6 weeks at most primary-care offices. Hims now has a direct partnership with Novo Nordisk for Wegovy, which it markets as "$1,999/year" or about $166/month for cash-pay patients in some configurations.
The strongest GLP-1 specialty platforms (in terms of clinical depth, not necessarily marketing budget) share these features:
Patients who fit a standard profile (clear obesity or diabetes diagnosis, no major contraindications, primary goal is weight loss or A1C reduction) and who value speed-to-prescription. The category has democratized access dramatically. The trade-off is less ongoing clinical relationship than a hormone optimization clinic provides.
The newest and fastest-changing lane. Examples: Lilly Direct (Zepbound), NovoCare (Wegovy).
Through 2022–2024, the brand-name pharmaceutical companies watched a substantial fraction of their GLP-1 economics flow to compounding pharmacies and to telehealth middlemen. The pharma response, accelerated through 2025, was to launch their own direct-to-consumer programs. Eli Lilly's Lilly Direct initially offered Zepbound at sharply reduced prices via vial formulations (rather than auto-injector pens). Novo Nordisk's NovoCare followed with Wegovy at $349/month cash-pay.
Authentic brand-name medication, manufactured under FDA-approved standards, shipped directly to the patient. A licensed prescriber is in the loop — manufacturers can't sell prescription drugs direct without one — but the consultation tends to be lightweight. The model is closer to "self-serve with a prescriber checkpoint" than full-service telehealth.
Less hand-holding through dose titration. Less support when you hit nausea at week three and aren't sure whether to push through, dose-reduce, or stop. Less help navigating insurance prior authorization (these programs are primarily cash-pay). For experienced patients who know the drug, these are non-issues. For first-time GLP-1 users, the lighter clinical layer is a real consideration.
Cost-conscious patients who already know the medication, are confident in the workflow, don't need active clinical support week-to-week, and want manufacturer-direct economics. Also the right channel for patients whose insurance won't cover GLP-1s and who are paying out of pocket regardless.
A different kind of business entirely. Examples: Defy Medical, Maximus, Lifeforce, Optispan, Function Health.
Broader peptide menus — testosterone optimization, growth hormone peptides (Sermorelin, CJC-1295, Tesamorelin), NAD+ infusions, and broader endocrine work. Some operate at the longevity-clinic end of the spectrum (deep biomarker testing, multi-quarter relationships, lifestyle protocols). Others focus narrowly on hormone optimization for men or women.
Materially more. A typical hormone optimization clinic enrollment runs $400–$1,500/month depending on lab work intensity, included medications, and whether you're on a peptide protocol. Function Health and similar biomarker-first services operate on annual memberships ($499–$2,000/year) plus visit fees. Most insurance won't cover this work, since most of it is technically off-label or wellness-coded.
Three things the GLP-1 specialty platforms typically don't provide: real labs (full hormone panels, metabolic markers, sometimes detailed imaging), real ongoing relationships (the same prescriber over time, who knows your trends), and broader prescribing menus (the option to layer growth hormone peptides, testosterone replacement, sleep optimization, etc., not just GLP-1s).
Patients who want a doctor who actually thinks about peptides for a living. Athletes, longevity-focused individuals, and people with complex hormonal pictures (low testosterone, hypothyroid, perimenopausal hormone shifts) where GLP-1s are one piece of a larger optimization picture rather than the whole project. Not the right channel for a patient who only wants Wegovy and a credit card transaction.
Six signals to evaluate any peptide telehealth provider against, regardless of lane:
No comparison can replace a real prescriber relationship. With that caveat, here's how thoughtful clinicians frame the choice:
Clear obesity or T2D diagnosis, want speed and support, comfortable with cash-pay or insurance prior auth.
Lean: Lane 01 (specialty telehealth)Knows the medication, doesn't need clinical hand-holding, paying cash, wants the lowest legitimate price.
Lean: Lane 02 (manufacturer direct)Low testosterone, perimenopausal symptoms, multiple medications, want ongoing physician relationship.
Lean: Lane 03 (hormone clinic)Want broader peptide menu (GH peptides, NAD+, etc.), interested in biomarker tracking, willing to pay for depth.
Lean: Lane 03 (longevity clinic)Established cardiovascular disease + overweight, OSA + obesity, T2D — insurance is likely to cover.
Lean: Lane 01 with insurance navigationNeed to transition to brand-name. Lane 02 is most cost-effective; Lane 01 if you want clinical support during the switch.
Lean: Lane 02 (or 01 with brand-name)1. "Will I be able to talk to my prescriber if I have a question or side effect?" The answer should be yes, with a specific channel (portal message, video visit, etc.) and a typical response time.
2. "Is this brand-name medication or compounded?" If compounded, ask what the documented clinical justification is. "It's cheaper" is not a justification.
3. "What's the cancellation policy?" Auto-renewal terms matter. Some platforms make it dramatically harder to cancel than to enroll.
Industry data, regulatory filings, and manufacturer disclosures — all primary or peer-reviewed:
Read the side-by-side of Tirzepatide, Semaglutide, and Retatrutide — mechanism, weight loss, safety, cost, and which one fits which goal.
Open the GLP-1 comparison